Short answer
Adicet Bio Inc (ACET) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Adicet Bio announced financial results for the quarter ended September 30, 2026.
Adicet Bio Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Adicet Bio announced financial results for the quarter ended September 30, 2026
- Full financial figures and management commentary appear in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Phase 1 prula-cel data showed 50% complete renal response and 54% DORIS remission at 12 months, supporting pivotal lupus development
- No Grade >2 CRS, ICANS, IEC-HS, or GvHD, strengthening potential outpatient use but requiring confirmation in larger studies
- Pivotal lupus nephritis study startup underway, with FDA expansion discussions planned in 4Q/2026 and approximately 22-patient follow-up data expected in 1Q/2027
- ADI-212 received FDA IND clearance and Fast Track Designation for mCRPC, with Phase 1 enrollment anticipated in 1Q/2027
- Cash $100.9M as of September 30, 2026, expected to fund operating expenses into the second half of 2027; nine-month net loss $60.5M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Adicet Bio Inc 8-K filings
Get the next ACET 8-K as it lands
Follow ACET for push alerts, or ask the research agent what this filing means.